Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of the American College of Cardiology

• Publication date

  2006-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JACC.2005.11.071PMID 16630999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

  2004cited by this paper
• Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial

  2004cited by this paper
• Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial

  2003cited by this paper
• A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial

  2003cited by this paper
• Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.

  2003cited by this paper
• Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

  2003cited by this paper
• Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

  2002cited by this paper
• V2-vasopressin receptor antagonists-mechanism of effect and clinical implications in hyponatraemia.

  1999cited by this paper
• Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure.

  1999cited by this paper
• Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.

  1998cited by this paper
• Sudden Cardiac Death in Heart Failure

  1998cited by this paper
• VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.

  1998cited by this paper
• Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.

  1998cited by this paper
• Upregulation of aquaporin-2 water channel expression in chronic heart failure rat.

  1997cited by this paper
• Sudden cardiac death in heart failure. The role of abnormal repolarization.

  1994cited by this paper
• Congestive Heart Failure

  1994cited by this paper
• Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.

  1994cited by this paper
• Renal Salt and Water Handling in Congestive Heart Failure

  1994cited by this paper
• Enhancement of vascular action of arginine vasopressin by diminished extracellular sodium concentration.

  1993cited by this paper
• Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

  1992cited by this paper
• Arginine vasopressin gene expression in chronic cardiac failure in rats.

  1990cited by this paper
• Arginine vasopressin and the renal response to water loading in congestive heart failure.

  1986cited by this paper
• Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.

  1986cited by this paper
• High plasma antidiuretic hormone in patients with cardiac failure: influence of age.

  1982cited by this paper
• Antidiuretic hormone in congestive heart failure.

  1982cited by this paper
• Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.

  1981cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion.

  1974cited by this paper

• Development of dual V1a/V2 antagonists containing triazolobenzazepine scaffold.

  2024cites this paper
• Challenges in diuretic therapy: A case-based discussion.

  2022cites this paper
• Vasopressin: a possible link between hypoxia and hypertension

  2022cites this paper
• Updates and Perspectives on Aquaporin-2 and Water Balance Disorders

  2021cites this paper
• Vasopressin Type 2 Receptor Agonists and Antagonists

  2021cites this paper
• Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model

  2019cites this paper
• Ultraschnell wirksame Betablocker Esmolol und Landiolol: Aktuelle Rolle in der Intensiv- und Notfallmedizin

  2019cites this paper
• Spectrofluorimetric methods for the determination of lixivaptan and its hydrolysis product in human plasma and urine, with factors optimization study

  2018cites this paper
• Hormone treatments in congestive heart failure

  2018cites this paper
• The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?

  2017cites this paper
• Management of Congestion and Diuretic Resistance in Heart Failure

  2016cites this paper
• Demographical and clinicopathological characteristics in heart failure and outcome predictors: a prospective, observational study

  2016cites this paper
• New Targets in the Drug Treatment of Heart Failure

  2016cites this paper
• Pathophysiology of Heart Failure and an Overview of Therapies

  2016cites this paper
• Development of Therapeutics for Heart Failure: Expedited Commentary.

  2016cites this paper
• An Improved, Scalable and Impurity-Free Process for Lixivaptan

  2015cites this paper
• Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials

  2015cites this paper
• The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure

  2015cites this paper
• Volume Overload in Heart Failure: An Evidence-Based Review of Strategies for Treatment and Prevention.

  2015cites this paper
• Capítulo 16 – Papel de los vaptanes en el tratamiento de la hiponatremia

  2015cites this paper
• Improving outcomes in patients with kidney disease : a practical application of evidence based medicine

  2015cites this paper
• [Hyponatremia in chronic heart failure].

  2014cites this paper
• Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders

  2014cites this paper
• Clinical Application of V 2 Receptor Antagonists

  2014cites this paper
• Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs.

  2014cites this paper
• Clinical Application of V2 Receptor Antagonists

  2014cites this paper
• Therapeutic potential of vasopressin-receptor antagonists in heart failure.

  2014cites this paper
• Arginine vasopressin as a target in the treatment of acute heart failure.

  2014cites this paper
• Emerging biomarkers for acute heart conditions

  2014cites this paper
• Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.

  2014cites this paper
• Pharmacologic Therapies for Chronic and Acute Decompensated Heart Failure: Specific Insights on Cardiorenal Syndromes

  2014cites this paper
• Disorders of Water Metabolism

  2013cites this paper
• Hyponatremia: an update on current pharmacotherapy

  2013cites this paper
• Hyponatraemia: more than just a marker of disease severity?

  2013cites this paper
• [Vasopressin receptor antagonists in therapy of congestive heart failure].

  2013cites this paper
• Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia

  2013cites this paper
• The Use of Vaptans in Clinical Endocrinology

  2013cites this paper
• Hyponatremia in patients with heart failure.

  2013cites this paper
• Clinical review: the use of vaptans in clinical endocrinology.

  2013cites this paper
• Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment

  2013cites this paper
• Copeptin: a new marker in cardiology.

  2013cites this paper
• Clinical management of SIADH

  2012cites this paper
• New weapoNs for MaNageMeNt of HypoNatreMia : VaptaNs

  2012cites this paper
• Therapeutic Potential of Vasopressin Receptor Antagonists

  2012cites this paper
• The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group study

  2012cites this paper
• Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia.

  2012cites this paper
• Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.

  2012cites this paper
• Assessment of Exposure of Metabolites in Preclinical Species and Humans at Steady State from the Single-Dose Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies: A Case Study

  2012cites this paper
• Hyponatremia now--a goldmine or a dead end?

  2012cites this paper
• Aquaporin 2: from its discovery to molecular structure and medical implications.

  2012cites this paper
• Risk stratification and short-term prognosis in acute heart failure syndromes: A review of novel biomarkers

  2011cites this paper
• Targeting Hyponatremia and Hemodynamics in Acute Decompensated Heart Failure: Is There a Role for Vasopressin Antagonists?

  2011cites this paper
• Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure

  2011cites this paper
• Vaptans for the treatment of hyponatremia

  2011cites this paper
• Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.

  2011cites this paper
• Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

  2011cites this paper
• The potential role for lixivaptan in heart failure and in hyponatremia

  2011influential citation
• Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy

  2011cites this paper
• Hyponatraemia and vasopressin in heart failure: markers or mediators?

  2011cites this paper
• [Vasopressin receptor antagonists: the vaptans].

  2010cites this paper
• Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.

  2010cites this paper
• New investigational drugs for the management of acute heart failure syndromes.

  2010cites this paper
• International Journal of Nephrology and Renovascular Disease

  2010cites this paper
• Vasopressin Antagonists: Pharmacotherapy for the Treatment of Heart Failure

  2010cites this paper
• Significance of hyponatremia in heart failure

  2010cites this paper
• Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.

  2010cites this paper
• Conivaptan for the treatment of hyponatremia

  2010cites this paper
• Hyponatremia in Heart Failure: Revisiting Pathophysiology and Therapeutic Strategies

  2010cites this paper
• Conivaptan for the treatment

  2010cites this paper
• May vaptans contribute to the treatment of refractory ascites?

  2010cites this paper
• Reviewin acute myocardial infarction

  2010cites this paper
• Vasopressin: a review of therapeutic applications.

  2010cites this paper
• Antagonistas del receptor de vasopresina: los vaptanes

  2010cites this paper
• Emerging therapies for heart failure: renal mechanisms and effects

  2010cites this paper
• The use of vasopressin receptor antagonists in hyponatremia.

  2010cites this paper
• Aquaporins in kidney pathophysiology

  2010cites this paper
• Managing hyponatremia in patients with heart failure.

  2010cites this paper
• The management of acute heart failure.

  2010cites this paper
• Vasopressin-receptor antagonists.

  2010cites this paper
• Evaluation of Toxicity for Heart Failure Therapeutics: Studying Effects on the QT Interval

  2010cites this paper
• Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study

  2010cites this paper
• The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.

  2010influential citation
• Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

  2010cites this paper
• Biomarkers in acute myocardial infarction

  2010cites this paper
• DISORDERS OF THE HYPOTHALAMIC-PITUITARY AXIS

  2009cites this paper
• Current and future treatment options in SIADH

  2009cites this paper
• Hyponatremia in Heart Failure: The Role of Arginine Vasopressin and Diuretics

  2009cites this paper
• Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.

  2009cites this paper
• AVP receptor antagonists in patients with CHF

  2009cites this paper
• Vasopressin and Vasopressin Receptor Antagonists in Heart Failure

  2009cites this paper
• Investigational vasopressin receptor modulators in the pipeline

  2009cites this paper
• Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure

  2009cites this paper
• VASOPRESSIN IN INTENSIVE CARE UNIT

  2009cites this paper
• Lixivaptan: a novel vasopressin receptor antagonist

  2009cites this paper
• Current drugs and medical treatment algorithms in the management of acute decompensated heart failure

  2009cites this paper
• FACTORES RELACIONADOS CON LA URGENCIA HIPERTENSIVA EN UN ÁREA DE SALUD URBANA DE SANTA CLARA

  2009cites this paper
• Vasopressin Antagonists in Physiology and Disease

  2009cites this paper
• Chapter 29 – Therapy of Dysnatremic Disorders

  2008cites this paper
• Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?

  2008cites this paper
• Treatment of hyponatremia.

  2008cites this paper